Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fabricant Ends Eventful Service In FDA Supplement Regulation To Head NPA

This article was originally published in The Tan Sheet

Executive Summary

Daniel Fabricant will be the CEO of NPA, and leave his post as director of FDA’s Division of Dietary Supplement Programs, the association announced April 8.

You may also be interested in...



FDA Dietary Supplement Programs Research, Strategy Official Moves To NPA

Sibyl Swift is responsible for developing and implementing NPA's educational, regulatory and compliance programs such as SSCI and the NPA Natural Standard. She also will assist members with claim reviews, substantiation and NDI notification policy.

NPA Internal Review Sparked Suit Against Board Members, Ongoing Changes

A review launched after NPA's former CFO filed a wrongful termination complaint in November refuted the allegations, but has "also shown that there was some governance that needed to change," says Executive Director and CEO Daniel Fabricant.

Dr. Oz Grilling In Senate Tops 2014 Dietary Supplement News

Articles on the potential that debate around the benefits of fish oils will damage consumer regard for omega-3 supplements, FDA’s guidance on distinguishing between liquid supplements and conventional beverages and Daniel Fabricant’s exit from FDA’s supplement regulation office also were highly read in 2014.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel